A Study of DXC014 in Patients With Advanced Solid Tumors.

Sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Study ID
NCT07177937
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DXC014 — DRUG
    Dose Escalation DXC014, Cohort Expansion DXC014

Study Details

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.

Key Dates

First listed
Sep 17, 2025
Start date
Mar 3, 2026
Status verified
Jul 2026
Primary completion
Oct 20, 2030
Completion
Oct 20, 2030

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    Dose Escalation DXC014, Cohort Expansion DXC014

Primary Outcome Measure

Number of participants that experienced dose limiting toxicities(DLTs) at given dose level. [ Time Frame: 28 days ]

Central Contacts

Find similar trials

Nationwide
Melanoma trialsProstate cancer trialsLung cancer trialsOncology trialsSkin cancer trialsDermatology trialsProstate oncology trialsMen's health trialsUrology trialsLung oncology trialsLung disease trials

Related Studies